Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Novavax, Inc. (Nasdaq: NVAX) has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under ...
The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...
Zacks Investment Research on MSN
What to expect from Pfizer's non-oncology business in Q4
Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...
Stocktwits on MSN
Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...
Third-quarter 2025 Cost of Sales(3) as a percentage of revenues decreased by 4.7 percentage points compared to the prior-year quarter, primarily driven by (i) a favorable revision of our estimate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback